Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GEN 3009

Next Previous
Search
Drug Profile

GEN 3009

Alternative Names: DuoHexaBody-CD37; GEN-3009; HexaBody®-CD37

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab
  • Developer AbbVie; Genmab
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunologic cytotoxicity; Phagocyte stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II B-cell lymphoma

Most Recent Events

  • 28 Jul 2023 Genmab terminates a phase I/II trial in B-cell lymphoma (Second-line therapy or greater, Combination therapy) in USA, Spain, Netherlands, Denmark, Belgium and France (IV) due to strategic evaluation of GEN3009 within context of Genmab's portfolio, decision not based on any safety or regulatory concerns (NCT04358458) (EudraCT2019-002752-16)
  • 30 Jun 2022 AbbVie and Genmab decides to discontinue the co-development and commercialization of GEN 3009
  • 22 Jun 2020 Pharmacodynamics data from preclinical studies in B-cell lymphoma models presented at the 111th Annual Meeting of the American Association for Cancer Research - II (AACR-2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top